ESR1 and breast carcinoma: These 422 BiNets were then subjected to survival analysis on five different breast cancer patient cohorts, i.e., the entire patients in the Netherlands Cancer Institute (NKI) dataset [20,21], the Lymph-Node-positive (LN-positive) patients in the NKI dataset, the Estrogen-Receptor-negative (ER-negative) patients in the NKI dataset, the entire patients in the GSE1456 (Stockholm) dataset [22], and the entire patients in the GSE2034 (Wang) dataset [23,24].